Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxtra Pharmaceuticals
Doylestown, Pennsylvania, United Statesoxtrapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oxtra Pharmaceuticals is a biotechnology company focused on developing innovative therapies for maternal health, specifically targeting conditions related to labor and delivery. The company's primary focus is on the development of OX-101, a novel, potent, and selective oxytocin receptor agonist designed to prevent and treat postpartum hemorrhage. By leveraging advanced medicinal chemistry, Oxtra aims to provide safer and more effective pharmacological options for obstetric care. The company is currently advancing its lead candidate through pre-clinical development with the goal of improving outcomes for mothers globally.
- Therapeutic areas
- Women's Health
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Oxtra Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxtra Pharmaceuticals.